Beleggen.nl
Uitgebreid zoeken
Markt MonitorMarkt Monitor

BioPharma Terug naar discussie overzicht

INSM - Insmed - Deel 15

2.002 Posts
Pagina: «« 1 ... 35 36 37 38 39 ... 101 »» | Laatste | Omlaag ↓
  2. [verwijderd] 3 juli 2007 13:02

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    ludwig mack schreef:

    ik plaats de koersen, als je dat al niet door had, om de draad levendig te houden ........;-)
    klopt en is top, maar ah/pm kan je weglaten bij lage omzetten

    dagomzet hi/low meer dan welkom zoals je al een tijdje post

    nog geen mail van dr allan over nieuwe tel afspraak
  5. [verwijderd] 4 juli 2007 21:42

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Slim!...In ieder geval gebeiteld voor't geval NVA of DNA of wie dan ook er met de kroonjuwelen vandoor wil gaan!

    Ook toevallig dat de vastlegging van dit patent samenvalt met de aankopen van Allan, Tully, Glover & Westpam!

    Abstract of US2007141069
    New methods for the treatment of human disease are provided. IGFBP- 3 is administered together with a co-administered agent to subjects having disease, thereby alleviating the symptoms of the disease, under conditions where administration of IGFBP- 3 alone at the maximum practicable dose has no measurable beneficial effect on the disease condition.

    Onder de tab Claims:

    Claims of US2007141069

    We claim:

    1. A method of treating a patient having a tumor that is unresponsive to IGFBP-3 alone, comprising administering to said patient a co-administered agent or treatment regimen together with an effective amount of IGFBP-3.

    2. The method of claim 1, wherein said co-administered agent is a chemical agent selected from the group consisting of alkylating agents, antimetabolites, Vinca alkaloids, podophyllotoxins, antitumor antibiotics, nitrosoureas, metallic DNA modifying compounds and microtubule stabilizers.

    3. The method of claim 1, wherein said co-administered agent is a biological agent selected from the group consisting of nutrient limitation, antibodies, vaccines, peptides, cytokines, receptor ligands and nucleic acids.

    4. The method of claim 1, wherein said co-administered agent is a physical agent selected from the group consisting of heat, pressure, osmolarity, acidity and radiation.

    5. The method of claim 2, wherein the cancer is selected from the group consisting of breast, prostate, colon, ovarian, pancreatic, gastric and lung cancer.

    6. The method of claim 5, wherein the co-administered agent is a chemical agent selected from the group consisting of doxorubicin, paclitaxel, methotrexate, tamoxifen, cyclophosphamide, vincristine, etoposide, streptozotocin and 5-fluorouracil.

    7. The method of claim 6, wherein said cancer is breast cancer.

    8. The method of claim 6, wherein said cancer is prostate cancer.

    9. The method of claim 6, wherein said cancer is colon cancer.

    10. The method of claim 6, wherein said cancer is lung cancer.

    11. The method of claim 6, wherein said co-administered agent is paclitaxel.

    12. The method of claim 6, wherein said co-administered agent is 5-fluorouracil.

    13. The method of claim 6, wherein said co-administered agent is doxorubicin.

    14. The method of claim 7, wherein said co-administered agent is paclitaxel.

    15. The method of claim 7, wherein said co-administered agent is 5-fluorouracil.

    16. The method of claim 7, wherein said co-administered agent is doxorubicin.

    17. The method of claim 8 wherein said co-administered agent is paclitaxel.

    18. The method of claim 8, wherein said co-administered agent is 5-fluorouracil.

    19. The method of claim 8, wherein said co-administered agent is doxorubicin.

    20. The method of claim 1, wherein said IGFBP-3 is administered at about 0.01 to about 50 milligrams per kilogram total body weight per day (mg/kg/day).

    21. A method for alleviating a symptom of cancer, comprising administering a co-administered agent or treatment regimen together with an effective amount of IGFBP-3 to a subject having cancer, wherein the administration of IGFBP-3 alone has no measurable effect on the symptom.
    tinyurl.com/2vh6lt

    Geluk, F.
  8. ludwig mack 5 juli 2007 15:50

    • ludwig mack

      Lid sinds: 30 jan 2004

      Laatste bezoek: 10 feb 2025

    • Aanbevelingen

      Ontvangen: 412

      Gegeven: 29

    •    Aantal posts: 8.675

    0,80 ( 15:44 ) 0,01 / 1,27%


    Laatste volume 1.100
    Volume 46.749

    Slot 0,79 3-7-2007
    Open 0,79 15:30
    Hoog 0,80 15:30
    Laag 0,79 15:30
  10. ludwig mack 6 juli 2007 00:05

    • ludwig mack

      Lid sinds: 30 jan 2004

      Laatste bezoek: 10 feb 2025

    • Aanbevelingen

      Ontvangen: 412

      Gegeven: 29

    •    Aantal posts: 8.675

    Last Trade: 0.78
    Trade Time: 3:59PM ET
    Change: 0.01 (1.27%)
    Prev Close: 0.79
    Open: 0.79
    Bid: 0.77 x 5000
    Ask: 0.80 x 800
    1y Target Est: 2.00

    Day's Range: 0.77 - 0.80
    52wk Range: 0.68 - 1.98
    Volume: 693,903
    Avg Vol (3m): 2,116,750
    Market Cap: 79.04M
    P/E (ttm): N/A
    EPS (ttm): -0.53
    Div & Yield: N/A (N/A)

  12. ludwig mack 6 juli 2007 00:18

    • ludwig mack

      Lid sinds: 30 jan 2004

      Laatste bezoek: 10 feb 2025

    • Aanbevelingen

      Ontvangen: 412

      Gegeven: 29

    •    Aantal posts: 8.675

    quote:

    marieke2 schreef:

    We zijn aan het afzakken,wanneer kunnen we nieuws verwachten mbt als of ander update?

    marieke, ik heb geen data in mijn agenda staan, op dit moment.
    dus even op eigen kracht de komkommertijd van de vakaties door; eind juli en begin augustus zal de koers zeker nog dalen, maar bodem ligt nu stevig op 70.
  13. ludwig mack 6 juli 2007 15:54

    • ludwig mack

      Lid sinds: 30 jan 2004

      Laatste bezoek: 10 feb 2025

    • Aanbevelingen

      Ontvangen: 412

      Gegeven: 29

    •    Aantal posts: 8.675

    Last Trade: 0.77
    Trade Time: 9:39AM ET
    Change: 0.01 (1.29%)
    Prev Close: 0.78
    Open: 0.77
    Bid: 0.76 x 2000
    Ask: 0.77 x 1400
    1y Target Est: 2.00

    Day's Range: 0.76 - 0.78
    52wk Range: 0.68 - 1.98
    Volume: 35,570
    Avg Vol (3m): 1,923,000
    Market Cap: 78.01M
    P/E (ttm): N/A
    EPS (ttm): -0.526
    Div & Yield: N/A (N/A)

  15. ludwig mack 6 juli 2007 23:05

    • ludwig mack

      Lid sinds: 30 jan 2004

      Laatste bezoek: 10 feb 2025

    • Aanbevelingen

      Ontvangen: 412

      Gegeven: 29

    •    Aantal posts: 8.675

    INSMED INC (NasdaqGM:INSM)

    After Hours: 0.87 0.10 (12.87%) as of 4:30PM ET on 07/06/07

    Last Trade: 0.7708
    Trade Time: 3:59PM ET
    Change: 0.0092 (1.18%)
    Prev Close: 0.78
    Open: 0.77
    Bid: 0.7500 x 2000
    Ask: 0.9690 x 10000
    1y Target Est: 2.00

    Day's Range: 0.7602 - 0.7800
    52wk Range: 0.68 - 1.98
    Volume: 602,100
    Avg Vol (3m): 1,901,150
    Market Cap: 78.10M
    P/E (ttm): N/A
    EPS (ttm): -0.526
    Div & Yield: N/A (N/A)


    na beurs plus 13 % ?
  17. [verwijderd] 6 juli 2007 23:23

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    DieGroeneGigant schreef:

    A grand total of 400 shares bought ah. Looks to me like someone wanted to buy at .78 and switched the numbers. Oops!

    it s a shame
  19. [verwijderd] 7 juli 2007 11:41

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    After Hours
    Last: $ .87 After Hours
    High: $ .89
    After Hours
    Volume: 400 After Hours
    Low: $ .87

    After Hours
    Time (ET) After Hours
    Price After Hours
    Share Volume
    16:30 $ .87 100
    16:28 $ .87 100
    16:27 $ .87 100
    16:25 $ .89 100




  20. [verwijderd] 9 juli 2007 09:03

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Blockbuster?... De juli uitgave geeft alle redenen om dit te vermoeden...Allan/Sommer/Sleevi/Clemmons...Al bekende namen.

    Allan koopt nog eens wat bij...De redenen worden meer en meer duidelijk!

    jcem.endojournals.org/cgi/content/abs...

    Results: Fasting glucose was reduced in the groups that received either 1 (32 ± 5% reduction) or 2 mg/kg·d (40 ± 6% reduction) of the complex. Mean daily glucose (four determinations) was reduced by 26 ± 4% in the 1 mg/kg group and by 33 ± 5% in the 2 mg/kg group compared with 18 ± 4% in the placebo group. Total serum IGF-I increased between 2.0 ± 0.3- and 5.7 ± 1.3-fold by d 8. IGFBP-3 concentrations increased significantly only in the 2 mg/kg group. IGF-II concentrations declined to values that were between 27 ± 4% and 64 ± 7% below baseline. Acid labile subunit concentrations declined significantly in the three highest dose groups. The sum of the IGF-I + IGF-II concentrations was significantly increased at the two highest dosages. There were very few drug-associated adverse events reported in this study with the exception of hypoglycemia, which occurred in 15 subjects who had received rhIGF-I/rhIGFBP-3 treatment.

    Conclusions: Administration of rhIGF-I/rhIGFBP-3 resulted in a redistribution of the amount of IGF-I and IGF-II that bound to IGFBP-3. Fasting and mean daily blood glucose were reduced significantly in the two highest dosage groups. The results suggest that both the total concentration of IGF-I as well as its distribution in blood may determine the extent to which insulin sensitivity is enhanced.

    Geluk, F.
  21. [verwijderd] 9 juli 2007 12:31

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0


    Frederick,

    mag ik vragen om welke vorm van diabetes 2het hier om gaat?Ik was er van overtuigd dat het hele diabetes verhaal een trca indicatie geworden was.
    Schiet me niet af als ik er helemaal naast zit.
2.002 Posts
Pagina: «« 1 ... 35 36 37 38 39 ... 101 »» | Laatste |Omhoog ↑

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 466 7.012
AB InBev 2 5.495
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.582 51.510
ABO-Group 1 22
Acacia Pharma 9 24.692
Accell Group 151 4.132
Accentis 2 264
Accsys Technologies 23 10.582
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 188
ADMA Biologics 1 34
Adomos 1 126
AdUX 2 457
Adyen 14 17.726
Aedifica 3 903
Aegon 3.258 322.686
AFC Ajax 538 7.087
Affimed NV 2 6.289
ageas 5.844 109.887
Agfa-Gevaert 14 2.049
Ahold 3.538 74.330
Air France - KLM 1.025 35.022
AIRBUS 1 11
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 467 13.036
Alfen 16 24.687
Allfunds Group 4 1.469
Almunda Professionals (vh Novisource) 651 4.251
Alpha Pro Tech 1 17
Alphabet Inc. 1 405
Altice 106 51.198
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.486 114.819
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.836 242.916
AMG 971 133.197
AMS 3 73
Amsterdam Commodities 305 6.687
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 490
Antonov 22.632 153.605
Aperam 92 14.975
Apollo Alternative Assets 1 17
Apple 5 381
Arcadis 252 8.767
Arcelor Mittal 2.033 320.656
Archos 1 1
Arcona Property Fund 1 286
arGEN-X 17 10.292
Aroundtown SA 1 219
Arrowhead Research 5 9.729
Ascencio 1 26
ASIT biotech 2 697
ASMI 4.108 39.088
ASML 1.766 106.398
ASR Nederland 21 4.452
ATAI Life Sciences 1 7
Atenor Group 1 485
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 32 13.647
Axsome Therapeutics 1 177
Azelis Group 1 64
Azerion 7 3.392